Molecular mass of semaglutide and why the figure differs between sources

Adding the measurement that the opening post says would settle it.

The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.

The reasoning is more useful than the number, which is why I have shown it.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

Worth reading the earlier posts in this thread before acting on mine.

Worth separating two things that post #36 runs together.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

The short answer was in the first line; everything after is the working.

The strongest argument against my own position on molecular mass of semaglutide, stated as well as I can state it, since nobody else has yet.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

That is all I can say without guessing.

I had written a reply contradicting post #68 and deleted it. Here is what survived.

Where the molecular mass of semaglutide reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.

Genuinely open to being wrong about this one.

The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.

I would put this at better than even and not much better.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

That is my reading. Someone else read the same page differently and was reasonable.